跳到主要导航 跳到搜索 跳到主要内容

Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells

  • Fei Liao
  • , Jing Zhang
  • , Yangyang Hu
  • , Alireza Hassani Najafabadi
  • , James J. Moon
  • , Max S. Wicha
  • , Bashir Kaspo
  • , Joel Whitfield
  • , Alfred E. Chang*
  • , Qiao Li*
  • *此作品的通讯作者
  • Univ Michigan
  • Huazhong Univ Sci & Technol

科研成果: 期刊稿件 › 论文 › 同行评审

27 引用 (Scopus)

摘要

Cancer immunotherapies may be limited by their failure to target cancer stem cells (CSCs). We previously described an approach to target these cells using a dendritic cell (DC) vaccine primed with lysates of CSCs identified by aldehyde dehydrogenase (ALDH). However, its clinical application is limited by the difficulty of obtaining adequate amounts of tumor from patient to make CSC lysate for vaccine preparation. To address this issue, we evaluated targeting ALDH(high) CSCs using two antigenic peptides derived from ALDH in D5 melanoma model in both protection and therapeutic settings. ALDH 1A1 or 1A3 peptide-DC vaccines primed cytotoxic T lymphocytes (CTLs) that specifically killed ALDH(high) D5 CSCs, with ALDH 1A1 + 1A3 dual peptides-DC vaccine mediating an additive CTL effect compared to single peptide-DC vaccines. In a tumor challenge model, ALDH peptide-DC vaccines induced significant protective immunity suppressing D5 tumor growth with the dual peptides-DC vaccine being superior to each peptide individually. In a therapeutic model, dual peptide-DC vaccine resulted in significant tumor growth suppression with anti-PD-L1 administration significantly augmenting this effect. Immune monitoring studies revealed that ALDH dual peptides-DC vaccination elicited strong T cell (CTL & IFN gamma Elispot) and antibody immunity targeting ALDH(high) CSCs, resulting in significant reduction of ALDH(high) D5 CSCs. ALDH dual peptides-DC vaccination plus anti-PD-L1 administration resulted in increased recruitment of CD3(+) TILs in the residual tumors and further reduction of ALDH(high) D5 CSCs. ALDH peptide(s)-based vaccine may allow for clinical translation via immunological targeting of ALDH(high) CSCs. Furthermore, this vaccine augments the efficacy of immune checkpoint blockade.
源语言英语
页(从-至)1959-1973
页数15
期刊Cancer Immunology, Immunotherapy
卷71
期8
早期在线日期1月 2022
DOI
出版状态已出版 - 8月 2022

基金资助

This work was partially supported by Medimmune Inc. (MW & QL, No.16-PAF05892) and Gillson Longenbaugh Foundation (AEC & QL, No.C304136). F.L., J.Z. and Y.H. were supported in part by the China Scholarship Council, Hubei Cancer Hospital, and TWuhan Union Hospital, respectively.

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

关键词

  • Aldehyde dehydrogenase
  • Peptide
  • Dendritic cells
  • Vaccine
  • Cancer stem cells
  • Immunotherapy

收录

  • SCIE
  • Scopus

学术指纹

探究 'Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells' 的科研主题。它们共同构成独一无二的学术指纹。

引用此